Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1997 1
1999 1
2001 2
2004 2
2005 1
2006 2
2007 2
2008 1
2009 3
2010 5
2011 5
2012 5
2013 1
2014 4
2015 5
2016 5
2017 14
2018 17
2019 18
2020 23
2021 21
2022 24
2023 38
2024 14

Text availability

Article attribute

Article type

Publication date

Search Results

183 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study.
Harrington KJ, Burtness B, Greil R, Soulières D, Tahara M, de Castro G Jr, Psyrri A, Brana I, Basté N, Neupane P, Bratland Å, Fuereder T, Hughes BGM, Mesia R, Ngamphaiboon N, Rordorf T, Wan Ishak WZ, Lin J, Gumuscu B, Swaby RF, Rischin D. Harrington KJ, et al. J Clin Oncol. 2023 Feb 1;41(4):790-802. doi: 10.1200/JCO.21.02508. Epub 2022 Oct 11. J Clin Oncol. 2023. PMID: 36219809 Free PMC article. Clinical Trial.
Overall survival improved with pembrolizumab-chemotherapy in the PD-L1 CPS 20 (HR, 0.62; 95% CI, 0.46 to 0.84), CPS 1 (HR, 0.64; 95% CI, 0.53 to 0.78), and total (HR, 0.71; 95% CI, 0.59 to 0.85) populations. The objective response rate on second-course pembrolizumab was 27 …
Overall survival improved with pembrolizumab-chemotherapy in the PD-L1 CPS 20 (HR, 0.62; 95% CI, 0.46 to 0.84), CPS 1 (HR, 0.64; 95% CI, 0.5 …
Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score.
Burtness B, Rischin D, Greil R, Soulières D, Tahara M, de Castro G Jr, Psyrri A, Brana I, Basté N, Neupane P, Bratland Å, Fuereder T, Hughes BGM, Mesia R, Ngamphaiboon N, Rordorf T, Wan Ishak WZ, Ge J, Swaby RF, Gumuscu B, Harrington K. Burtness B, et al. J Clin Oncol. 2022 Jul 20;40(21):2321-2332. doi: 10.1200/JCO.21.02198. Epub 2022 Mar 25. J Clin Oncol. 2022. PMID: 35333599 Free PMC article. Clinical Trial.
PURPOSE: The phase III KEYNOTE-048 (ClinicalTrials.gov identifier: NCT02358031) trial of pembrolizumab in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) included planned efficacy analyses in the total population and in participants with programmed dea …
PURPOSE: The phase III KEYNOTE-048 (ClinicalTrials.gov identifier: NCT02358031) trial of pembrolizumab in recurrent or metastatic (R/M) head …
Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study.
Psyrri A, Fayette J, Harrington K, Gillison M, Ahn MJ, Takahashi S, Weiss J, Machiels JP, Baxi S, Vasilyev A, Karpenko A, Dvorkin M, Hsieh CY, Thungappa SC, Segura PP, Vynnychenko I, Haddad R, Kasper S, Mauz PS, Baker V, He P, Evans B, Wildsmith S, Olsson RF, Yovine A, Kurland JF, Morsli N, Seiwert TY; KESTREL Investigators. Psyrri A, et al. Ann Oncol. 2023 Mar;34(3):262-274. doi: 10.1016/j.annonc.2022.12.008. Epub 2022 Dec 16. Ann Oncol. 2023. PMID: 36535565 Free article. Clinical Trial.
BACKGROUND: Patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) have a poor prognosis. The phase III KESTREL study evaluated the efficacy of durvalumab [programmed death-ligand 1 (PD-L1) antibody] with or without tremelimumab [cytotoxic …
BACKGROUND: Patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) have a poor prognosis. The phase …
Constructing heterogeneous single-cell landscape and identifying microenvironment molecular characteristics of primary and lymphatic metastatic head and neck squamous cell carcinoma.
Zhang J, Liu Y, Xia L, Zhen J, Gao J, Atsushi T. Zhang J, et al. Comput Biol Med. 2023 Oct;165:107459. doi: 10.1016/j.compbiomed.2023.107459. Epub 2023 Sep 9. Comput Biol Med. 2023. PMID: 37713790 Free article.
We identified three microenvironment-based HNSCC subtypes associated with the prognosis of HNSCC patients. CONCLUSIONS: In summary, the present study dissected the intratumoral heterogeneity and immune microenvironment of primary and metastatic HNSCC, which is crucial to r …
We identified three microenvironment-based HNSCC subtypes associated with the prognosis of HNSCC patients. CONCLUSIONS: In summary, t …
Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in Older Patients: Are New Agents Bringing New Hope?
Cossu Rocca M, Lorini L, Szturz P, Bossi P, Vermorken JB. Cossu Rocca M, et al. Drugs Aging. 2023 Feb;40(2):135-143. doi: 10.1007/s40266-022-01000-6. Epub 2023 Jan 30. Drugs Aging. 2023. PMID: 36715829 Review.
They often recur or are progressive despite multimodality treatment approaches, resulting in a poor prognosis. Given the progressive aging of the global population, the probability to plan an active and eventually toxic treatment for an older patient, with either curative …
They often recur or are progressive despite multimodality treatment approaches, resulting in a poor prognosis. Given the progressive …
Patterns of recurrence in head and neck squamous cell carcinoma to inform personalized surveillance protocols.
Haring CT, Kana LA, Dermody SM, Brummel C, McHugh JB, Casper KA, Chinn SB, Malloy KM, Mierzwa M, Prince MEP, Rosko AJ, Shah J, Stucken CL, Shuman AG, Brenner JC, Spector ME, Worden FP, Swiecicki PL. Haring CT, et al. Cancer. 2023 Sep 15;129(18):2817-2827. doi: 10.1002/cncr.34823. Epub 2023 May 10. Cancer. 2023. PMID: 37162461
Univariate and multivariate analysis identified patterns of recurrence and predictors of survival. RESULTS: Median overall survival (mOS) improved over time (6.7 months in 1998-2007 to 11.8 months in 2008-2019, p = .006). Predictors of worse mOS included human papil …
Univariate and multivariate analysis identified patterns of recurrence and predictors of survival. RESULTS: Median overall survival ( …
Association of a gene-expression subtype to outcome and treatment response in patients with recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab.
Serafini MS, Cavalieri S, Licitra L, Pistore F, Lenoci D, Canevari S, Airoldi M, Cossu Rocca M, Strojan P, Kuhar CG, Merlano M, Perrone F, Vingiani A, Denaro N, Perri F, Argiris A, Gurizzan C, Ghi MG, Cassano A, Allegrini G, Bossi P, De Cecco L. Serafini MS, et al. J Immunother Cancer. 2024 Jan 30;12(1):e007823. doi: 10.1136/jitc-2023-007823. J Immunother Cancer. 2024. PMID: 38290766 Free PMC article. Clinical Trial.
The reported benefit in clinical trials is variable and heterogeneous. Our study aims at exploring and comparing the predictive role of gene-expression signatures with classical biomarkers for immunotherapy-treated R/M HNSCC patients in a multicentric phase IIIb trial. ... …
The reported benefit in clinical trials is variable and heterogeneous. Our study aims at exploring and comparing the predictive role …
Nutritional status associates with immunotherapy clinical outcomes in recurrent or metastatic head and neck squamous cell carcinoma patients.
Hernando-Calvo A, Mirallas O, Marmolejo D, Saavedra O, Vieito M, Assaf Pastrana JD, Aguilar S, Bescós C, Lorente J, Giralt J, Benavente S, Temprana-Salvador J, Alberola M, Dienstmann R, Garralda E, Felip E, Villacampa G, Brana I. Hernando-Calvo A, et al. Oral Oncol. 2023 May;140:106364. doi: 10.1016/j.oraloncology.2023.106364. Epub 2023 Mar 28. Oral Oncol. 2023. PMID: 36989964 Free article.
Analyzed variables at baseline included: clinicopathological, laboratory, and variables reflecting the host nutritional status such as the prognostic nutritional index (PNI) and albumin. The primary endpoint was progression free survival (PFS). ...Univariable and multivari …
Analyzed variables at baseline included: clinicopathological, laboratory, and variables reflecting the host nutritional status such as the …
183 results